IBD cancer and serious infections in Europe (I-CARE study)

Best Practice Nordic | Maalis 2019 | ECCO 2019 |

Prospective studies specifically assessing the effectiveness and safety profile of current therapeutic strategies based on a wider use of biologics in inflammatory bowel disease (IBD) are lacking. The overall objectives of I-CARE -a European prospective observationalstudy -are to assess: 1) the long-term safety profile (malignancy, infections) of immunomodulators (IMM), biologics (anti-TNF and vedolizumab) alone or in combination with an Iimmunomodulator 2) the potential for disease modification of biologics 3) the benefit-risk ratio of current therapeutic strategies 4) health economics of IBD care